Cargando…

Clinical, Biochemical and Genetic Variables Associated With Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders Using Second-Generation Antipsychotics: A Systematic Review

Background: Individuals with severe mental illness experience increased morbidity and mortality compared to the general population. Adverse effects of antipsychotics, including weight gain, may contribute to the development of metabolic syndrome (MetS), which is associated with increased risks of al...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sneller, Marius H., de Boer, Nini, Everaars, Sophie, Schuurmans, Max, Guloksuz, Sinan, Cahn, Wiepke, Luykx, Jurjen J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044798/ https://www.ncbi.nlm.nih.gov/pubmed/33868046 http://dx.doi.org/10.3389/fpsyt.2021.625935

Ejemplares similares

En attendant Godot: Waiting for the Funeral of “Schizophrenia” and the Baby Shower of the Psychosis Spectrum
por: Guloksuz, Sinan, et al.
Publicado: (2021)

Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial
por: de Boer, Nini, et al.
Publicado: (2021)

Editorial: Substance use and the psychosis spectrum
por: Kirli, Umut, et al.
Publicado: (2022)

Impaired Cerebellar Functional Connectivity in Schizophrenia Patients and Their Healthy Siblings
por: Collin, Guusje, et al.
Publicado: (2011)

Predictors for Antipsychotic Dosage Change in the First Year of Treatment in Schizophrenia Spectrum and Bipolar Disorders
por: Ringen, Petter Andreas, et al.
Publicado: (2019)

Impact of the first COVID-19 outbreak on mental health service utilisation at a Dutch mental health centre: retrospective observational study
por: Chow, Man Wei, et al.
Publicado: (2021)

Low Physical Activity and Cardiorespiratory Fitness in People With Schizophrenia: A Comparison With Matched Healthy Controls and Associations With Mental and Physical Health
por: Scheewe, Thomas W., et al.
Publicado: (2019)

Phenome-wide and genome-wide analyses of quality of life in schizophrenia
por: Pazoki, Raha, et al.
Publicado: (2020)

In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine
por: Luykx, Jurjen J., et al.
Publicado: (2020)

Phenome-wide and genome-wide analyses of quality of life in schizophrenia – ERRATUM
por: Pazoki, Raha, et al.
Publicado: (2021)

Estimating Aggregate Environmental Risk Score in Psychiatry: The Exposome Score for Schizophrenia
por: Pries, Lotta-Katrin, et al.
Publicado: (2021)

Analysis of GWAS-Derived Schizophrenia Genes for Links to Ischemia-Hypoxia Response of the Brain
por: Schmidt-Kastner, Rainald, et al.
Publicado: (2020)

Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome
por: Kornetova, Elena G., et al.
Publicado: (2019)

Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians’ perceptions of adherence vs. pharmacy claims
por: Stephenson, J J, et al.
Publicado: (2012)

Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
por: MacKenzie, Nicole E., et al.
Publicado: (2018)

Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia
por: Amato, Davide, et al.
Publicado: (2019)

Influence of antipsychotics on metabolic syndrome risk in patients with schizophrenia
por: Koricanac, Aleksandra, et al.
Publicado: (2022)

Assessing causal links between metabolic traits, inflammation and schizophrenia: a univariable and multivariable, bidirectional Mendelian-randomization study
por: Lin, Bochao D, et al.
Publicado: (2019)

Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia
por: Taipale, Heidi, et al.
Publicado: (2022)

Readmission Rates of Patients with Schizophrenia Treated with Depot Antipsychotics versus Oral Antipsychotics in a Community Hospital
por: Espiridion, Eduardo D, et al.
Publicado: (2018)

Successful high dose antipsychotic treatment with cariprazine in patients on the schizophrenia spectrum: Real-world evidence from a Spanish hospital setting
por: Galmes, Lluis Niell, et al.
Publicado: (2023)

Brain Networks Reveal the Effects of Antipsychotic Drugs on Schizophrenia Patients and Controls
por: Towlson, Emma K., et al.
Publicado: (2019)

Antipsychotics-induced improvement of cool executive function in individuals living with schizophrenia
por: Si, Yajing, et al.
Publicado: (2023)

The efficacy of antipsychotics in the treatment of physical aggressive behavior in patients with dementia in nursing homes
por: Nawzad, Sina, et al.
Publicado: (2022)

Lifestyle interventions for people with a severe mental illness living in supported housing: A systematic review and meta-analysis
por: Koomen, Lisanne E. M., et al.
Publicado: (2022)

Antipsychotic medication for women with schizophrenia spectrum disorders
por: Brand, Bodyl A., et al.
Publicado: (2022)

Association of Serotonin(2c) Receptor Polymorphisms With Antipsychotic Drug Response in Schizophrenia
por: Li, Jiang, et al.
Publicado: (2019)

Schizophrenia treatment with a combination of two LAI antipsychotics: A case report
por: Jarosz, Marcin, et al.
Publicado: (2022)

Adverse effects of antipsychotics on sleep in patients with schizophrenia. Systematic review and meta-analysis
por: Valencia Carlo, Yarmila Elena, et al.
Publicado: (2023)

Genetic and Metabolite Variability in One-Carbon Metabolism Applied to an Insulin Resistance Model in Patients With Schizophrenia Receiving Atypical Antipsychotics
por: Ward, Kristen M., et al.
Publicado: (2021)

Cognitive Behavioral Therapy for Insomnia as Adjunctive Therapy to Antipsychotics in Schizophrenia: A Case Report
por: Izuhara, Muneto, et al.
Publicado: (2018)

Treatment Responses of Cognitive Function and Plasma Asymmetric Dimethylarginine to Atypical Antipsychotic in Patients With Schizophrenia
por: Yu, Zhi-min, et al.
Publicado: (2019)

Targeting mGlu Receptors for Optimization of Antipsychotic Activity and Disease-Modifying Effect in Schizophrenia
por: Nicoletti, Ferdinando, et al.
Publicado: (2019)

The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective
por: Hjorth, Stephan
Publicado: (2021)

Prescription of Anticholinergic Drugs in Patients With Schizophrenia: Analysis of Antipsychotic Prescription Patterns and Hospital Characteristics
por: Hori, Hikaru, et al.
Publicado: (2022)

Effects of adjunctive pimavanserin and current antipsychotic treatment on QT interval prolongation in patients with schizophrenia
por: Bugarski-Kirola, Dragana, et al.
Publicado: (2022)

Adding Suicide Prevention to the Triple Advantages of Injectable Long-Acting Second-Generation Antipsychotics
por: Pompili, Maurizio
Publicado: (2020)

Antipsychotic medication for women with schizophrenia spectrum disorders – CORRIGENDUM
por: Brand, Bodyl A., et al.
Publicado: (2023)

Gyrification Connectomes in Unmedicated Patients With Schizophrenia and Following a Short Course of Antipsychotic Drug Treatment
por: Nelson, Eric A., et al.
Publicado: (2018)

Serum Epidermal Growth Factor is Low in Schizophrenia and Not Affected by Antipsychotics Alone or Combined With Electroconvulsive Therapy
por: Zhang, Xiaobin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gr5q7mrm27pteasm3o9ag4lsah